Abstract
Background: Multiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard-risk MM, and it has been suggested to portend a worse prognosis in African Americans in comparison with Whites. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM of African American and White descent. Methods: This study evaluated 3538 patients who underwent autologous hematopoietic cell transplantation (autoHCT) for MM from 2008 to 2016 and were reported to the CIBMTR. Patients were analyzed in 4 groups: African Americans with t(11;14) (n = 117), African Americans without t(11;14) (n = 968), Whites with t(11;14) (n = 266), and Whites without t(11;14) (n = 2187). Results: African Americans with t(11;14) were younger, had lower Karnofsky scores, and had more advanced stage MM with a higher Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI). Fewer African Americans with t(11;14) (21%) had a coexistent high-risk marker in comparison with Whites with t(11;14) (27%). In a multivariate analysis, race and t(11;14) had no association with progression-free survival. However, overall survival was superior among African Americans with t(11;14) in comparison with Whites with t(11;14) (hazard ratio, 0.53; 95% confidence interval, 0.30-0.93; P =.03). Survival was also associated with female sex, stage, time from diagnosis to transplant, a low HCT-CI, and receipt of maintenance. Conclusions: Race may have a differential impact on the survival of patients with t(11;14) MM who undergo autoHCT and needs to be further studied.
| Original language | English |
|---|---|
| Pages (from-to) | 82-92 |
| Number of pages | 11 |
| Journal | Cancer |
| Volume | 127 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2020 |
Keywords
- myeloma
- outcomes
- race
- t(11;14)
- transplant
Fingerprint
Dive into the research topics of 'African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cancer, Vol. 127, No. 1, 01.01.2020, p. 82-92.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States
AU - Badar, Talha
AU - Hari, Parameswaran
AU - Dávila, Omar
AU - Fraser, Raphael
AU - Wirk, Baldeep
AU - Dhakal, Binod
AU - Freytes, Cesar O.
AU - Rodriguez Valdes, Cesar
AU - Lee, Cindy
AU - Vesole, David H.
AU - Malek, Ehsan
AU - Hildebrandt, Gerhard C.
AU - Landau, Heather
AU - Murthy, Hemant S.
AU - Lazarus, Hillard M.
AU - Berdeja, Jesus G.
AU - Meehan, Kenneth R.
AU - Solh, Melhem
AU - Diaz, Miguel Angel
AU - Kharfan-Dabaja, Mohamed A.
AU - Callander, Natalie S.
AU - Farhadfar, Nosha
AU - Bashir, Qaiser
AU - Kamble, Rammurti T.
AU - Vij, Ravi
AU - Munker, Reinhold
AU - Kyle, Robert A.
AU - Chhabra, Saurabh
AU - Hashmi, Shahrukh
AU - Ganguly, Siddhartha
AU - Jagannath, Sundar
AU - Nishihori, Taiga
AU - Nieto, Yago
AU - Kumar, Shaji
AU - Shah, Nina
AU - D’Souza, Anita
N1 - Funding Information: Parameswaran Hari reports grants and personal fees from Amgen, Bristol‐Myers Squibb, Takeda, Janssen, and Pharmacyclics and personal fees from Karyopharm and Sanofi. Binod Dhakal reports belonging to advisory boards for Amgen, Takeda, GlaxoSmithKline, and Janssen and receiving an honorarium from Celgene. Cesar Rodriguez Valdes reports personal fees from Bristol‐Myers Squibb, Amgen, and Takeda. David H. Vesole reports belonging to speakers' bureaus for Amgen, Celgene, and Takeda. Ehsan Malek reports grants from MedPacto and Cumberland and personal fees from Takeda, Celgene, Secure Bio, Oncopeptides, Amgen, Sanofi, and Janssen. Gerhard C. Hildebrandt reports advisory roles with Pfizer, Kite Pharma, Incyte, and Jazz Pharmaceuticals; research funding from Pharmacyclics, Takeda, and Jazz Pharmaceuticals; and travel/accommodations/expenses from Kite Pharma, Incyte, Pfizer, the Falk Foundation, Jazz Pharmaceuticals, and Astellas Pharma. Heather Landau reports grants from Genzyme Corporation, Amgen, Ortho Biotech Clinical Affairs, Millennium Pharmaceuticals, Berlex, philanthropic funds, Astex, and the Amyloidosis Foundation and grants and personal fees from Takeda. Hillard M. Lazarus reports belonging to a data safety monitoring board (chimeric antigen receptor T‐cell studies) for Celgene/Bristol‐Myers Squibb. Jesus G. Berdeja reports funding from AbbVie, Amgen, Acetylon, Bluebird, Bristol‐Myers Squibb, Celgene, Celularity, Constellation, CRISPR Therapeutics, Curis, EMD Serono, Genentech, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, and Vivolux and consultancy for Takeda, Bristol‐Myers Squibb, Karyopharm, CRISPR Therapeutics, Celgene, Kite Pharma, Legend, Secura Bio, Servier, Janssen, Amgen, Bioclinica, and Prothena. Mohamed A. Kharfan‐Dabaja reports consultancy for Pharmacyclics and Daiichi Sankyo. Qaiser Bashir reports receiving research funding from Takeda, Stemline, and Acrotech and belonging to advisory boards for Spectrum, Kite Pharma, Takeda, and Purdue Pharma. Siddhartha Ganguly reports personal fees from Seattle Genetics. Taiga Nishihori reports research support for his institution from Novartis and Karyopharm. Shaji Kumar reports grants/clinical trial support to his institution from Bristol‐Myers Squibb/Celgene, Takeda, AbbVie, Roche, Medimmune, TeneoBio, CARsgen, and Janssen and personal fees (for consulting) from Oncopeptides. Anita D’Souza reports funding from Merck, Prothena, Sanofi, Mundipharma EDO, TeneoBio, and Takeda and has received consulting fees from Prothena, Pfizer, Imbrium, and Akcea. The other authors made no disclosures. Funding Information: The Center for International Blood and Marrow Transplant Research (CIBMTR) is supported primarily by Public Health Service grant U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; U24HL138660 from the NHLBI and the NCI; OT3HL147741, R21HL140314, and U01HL128568 from the NHLBI; HHSH250201700006C, SC1MC31881-01-00, and HHSH250201700007C from the Health Resources and Services Administration; and N00014-18-1-2850, N00014-18-1-2888, and N00014-20-1-2705 from the Office of Naval Research. Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01CA218285, R01CA231141, R01HL126589, R01AI128775, R01HL129472, R01HL130388, R01HL131731, U01AI069197, U01AI126612, and the Biomedical Advanced Research and Development Authority. Support is also provided by Be the Match Foundation, Boston Children's Hospital, Dana-Farber, the Japan Hematopoietic Cell Transplantation Data Center, St. Baldrick's Foundation, the National Marrow Donor Program, the Medical College of Wisconsin, and the following commercial entities: AbbVie, Actinium Pharmaceuticals, Inc, Adaptive Biotechnologies, Adienne SA, AlloVir, Inc, Amgen, Inc, Anthem, Inc, Astellas Pharma US, AstraZeneca, Atara Biotherapeutics, Inc, Bluebird Bio, Inc, Bristol-Myers Squibb, Celgene Corp, Chimerix, Inc, CSL Behring, CytoSen Therapeutics, Inc, Daiichi Sankyo Co, Ltd, Gamida Cell, Ltd, Genzyme, GlaxoSmithKline, HistoGenetics, Inc, Incyte Corporation, Janssen Biotech, Inc, Janssen Pharmaceuticals, Inc, Janssen/Johnson & Johnson, Jazz Pharmaceuticals, Inc, Kiadis Pharma, Kite Pharma, Kyowa Kirin, Legend Biotech, Magenta Therapeutics, Mallinckrodt LLC, Medac GmbH, Merck & Company, Inc, Merck Sharp & Dohme Corp, Mesoblast, Millennium, Takeda Oncology Co, Miltenyi Biotec, Inc, Novartis Oncology, Novartis Pharmaceuticals Corporation, Omeros Corporation, OncoImmune, Inc, Orca Biosystems, Inc, Pfizer, Inc, Pharmacyclics LLC, Regeneron Pharmaceuticals, Inc, REGiMMUNE Corp, Sanofi Genzyme, Seattle Genetics, Sobi, Inc, Takeda Oncology, Takeda Pharma, Terumo BCT, Viracor Eurofins, and Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health (NIH), the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US Government. CIBMTR supports the accessibility of research in accordance with the NIH data sharing policy and the NCI Cancer Moonshot public access and data sharing policy. The CIBMTR releases only de-identified data sets that comply with all relevant global regulations regarding privacy and confidentiality. The University of Texas MD Anderson Cancer Center is supported by the NIH (grant P30 CA016672). Funding Information: The Center for International Blood and Marrow Transplant Research (CIBMTR) is supported primarily by Public Health Service grant U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; U24HL138660 from the NHLBI and the NCI; OT3HL147741, R21HL140314, and U01HL128568 from the NHLBI; HHSH250201700006C, SC1MC31881‐01‐00, and HHSH250201700007C from the Health Resources and Services Administration; and N00014‐18‐1‐2850, N00014‐18‐1‐2888, and N00014‐20‐1‐2705 from the Office of Naval Research. Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01CA218285, R01CA231141, R01HL126589, R01AI128775, R01HL129472, R01HL130388, R01HL131731, U01AI069197, U01AI126612, and the Biomedical Advanced Research and Development Authority. Support is also provided by Be the Match Foundation, Boston Children's Hospital, Dana‐Farber, the Japan Hematopoietic Cell Transplantation Data Center, St. Baldrick's Foundation, the National Marrow Donor Program, the Medical College of Wisconsin, and the following commercial entities: AbbVie, Actinium Pharmaceuticals, Inc, Adaptive Biotechnologies, Adienne SA, AlloVir, Inc, Amgen, Inc, Anthem, Inc, Astellas Pharma US, AstraZeneca, Atara Biotherapeutics, Inc, Bluebird Bio, Inc, Bristol‐Myers Squibb, Celgene Corp, Chimerix, Inc, CSL Behring, CytoSen Therapeutics, Inc, Daiichi Sankyo Co, Ltd, Gamida Cell, Ltd, Genzyme, GlaxoSmithKline, HistoGenetics, Inc, Incyte Corporation, Janssen Biotech, Inc, Janssen Pharmaceuticals, Inc, Janssen/Johnson & Johnson, Jazz Pharmaceuticals, Inc, Kiadis Pharma, Kite Pharma, Kyowa Kirin, Legend Biotech, Magenta Therapeutics, Mallinckrodt LLC, Medac GmbH, Merck & Company, Inc, Merck Sharp & Dohme Corp, Mesoblast, Millennium, Takeda Oncology Co, Miltenyi Biotec, Inc, Novartis Oncology, Novartis Pharmaceuticals Corporation, Omeros Corporation, OncoImmune, Inc, Orca Biosystems, Inc, Pfizer, Inc, Pharmacyclics LLC, Regeneron Pharmaceuticals, Inc, REGiMMUNE Corp, Sanofi Genzyme, Seattle Genetics, Sobi, Inc, Takeda Oncology, Takeda Pharma, Terumo BCT, Viracor Eurofins, and Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health (NIH), the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US Government. CIBMTR supports the accessibility of research in accordance with the NIH data sharing policy and the NCI Cancer Moonshot public access and data sharing policy. The CIBMTR releases only de‐identified data sets that comply with all relevant global regulations regarding privacy and confidentiality. The University of Texas MD Anderson Cancer Center is supported by the NIH (grant P30 CA016672). Publisher Copyright: © 2020 American Cancer Society
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: Multiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard-risk MM, and it has been suggested to portend a worse prognosis in African Americans in comparison with Whites. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM of African American and White descent. Methods: This study evaluated 3538 patients who underwent autologous hematopoietic cell transplantation (autoHCT) for MM from 2008 to 2016 and were reported to the CIBMTR. Patients were analyzed in 4 groups: African Americans with t(11;14) (n = 117), African Americans without t(11;14) (n = 968), Whites with t(11;14) (n = 266), and Whites without t(11;14) (n = 2187). Results: African Americans with t(11;14) were younger, had lower Karnofsky scores, and had more advanced stage MM with a higher Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI). Fewer African Americans with t(11;14) (21%) had a coexistent high-risk marker in comparison with Whites with t(11;14) (27%). In a multivariate analysis, race and t(11;14) had no association with progression-free survival. However, overall survival was superior among African Americans with t(11;14) in comparison with Whites with t(11;14) (hazard ratio, 0.53; 95% confidence interval, 0.30-0.93; P =.03). Survival was also associated with female sex, stage, time from diagnosis to transplant, a low HCT-CI, and receipt of maintenance. Conclusions: Race may have a differential impact on the survival of patients with t(11;14) MM who undergo autoHCT and needs to be further studied.
AB - Background: Multiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard-risk MM, and it has been suggested to portend a worse prognosis in African Americans in comparison with Whites. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM of African American and White descent. Methods: This study evaluated 3538 patients who underwent autologous hematopoietic cell transplantation (autoHCT) for MM from 2008 to 2016 and were reported to the CIBMTR. Patients were analyzed in 4 groups: African Americans with t(11;14) (n = 117), African Americans without t(11;14) (n = 968), Whites with t(11;14) (n = 266), and Whites without t(11;14) (n = 2187). Results: African Americans with t(11;14) were younger, had lower Karnofsky scores, and had more advanced stage MM with a higher Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI). Fewer African Americans with t(11;14) (21%) had a coexistent high-risk marker in comparison with Whites with t(11;14) (27%). In a multivariate analysis, race and t(11;14) had no association with progression-free survival. However, overall survival was superior among African Americans with t(11;14) in comparison with Whites with t(11;14) (hazard ratio, 0.53; 95% confidence interval, 0.30-0.93; P =.03). Survival was also associated with female sex, stage, time from diagnosis to transplant, a low HCT-CI, and receipt of maintenance. Conclusions: Race may have a differential impact on the survival of patients with t(11;14) MM who undergo autoHCT and needs to be further studied.
KW - myeloma
KW - outcomes
KW - race
KW - t(11;14)
KW - transplant
UR - http://www.scopus.com/inward/record.url?scp=85091313309&partnerID=8YFLogxK
U2 - 10.1002/cncr.33208
DO - 10.1002/cncr.33208
M3 - Article
C2 - 32966625
AN - SCOPUS:85091313309
SN - 0008-543X
VL - 127
SP - 82
EP - 92
JO - Cancer
JF - Cancer
IS - 1
ER -